
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc. presents an attractive valuation supported by a net present value (NPV) analysis indicating significant upside potential from current share prices. The company's investigational drug assets, particularly IGC-AD1, have demonstrated encouraging results in preclinical studies for combating Alzheimer's disease, highlighting the effectiveness in addressing critical disease hallmarks. Additionally, ongoing advancements and the anticipation of positive data are expected to act as catalysts for stock performance moving forward.
Bears say
IGC Pharma Inc reported a net loss of $1.6 million, translating to an earnings per share (EPS) of $(0.02), which aligns with the company's prior estimates but raises concerns about ongoing financial viability. The company faces significant risks including liquidity issues, potential failure of its investigational drug candidates to prove safety and efficacy, and challenges related to regulatory approvals and market commercialization. Furthermore, external factors such as competition and changing investor sentiment towards biotech stocks add further uncertainty to the company's future performance and stock outlook.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares